Evidence map›Paper›PMID 35017194›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Modeling Multicancer Screening.

Stephen W Duffy, Peter Sasieni

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Stephen W DuffyCentre for Cancer Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square, London, United Kingdom. s.w.duffy@qmul.ac.uk.ORCID 0000-0003-4901-7922
Peter SasieniSchool of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom.

Funding

Cancer Research UK 25356
6 · The paper itself

Abstract

Jiao and colleagues have developed an estimation framework for measuring the benefits of a multi-cancer screening test, notably in terms of cancer detection and deaths prevented. The approach is clear and attractive. Further developments are likely to include more flexible modeling of sensitivities and specificities.

Indexed as

Mass ScreeningNeoplasmsEarly Detection of CancerHumansResearchSensitivity and Specificity

Identifiers

PMID35017194

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.